1. previous treatment with convalescent plasma for covid-19. 2. current use of investigational antiviral therapy targeting sars-cov-2. 3. history of anaphylactic transfusion reaction. 4. clinical diagnosis of acute decompensated heart failure. 5. objection to blood transfusion.

1. previous treatment with convalescent plasma for covid-19. 2. current use of investigational antiviral therapy targeting sars-cov-2. 3. history of anaphylactic transfusion reaction. 4. clinical diagnosis of acute decompensated heart failure. 5. objection to blood transfusion.

previous treatment with convalescent plasma for covid-19. current use of investigational antiviral therapy targeting sars-cov-2. history of anaphylactic transfusion reaction. clinical diagnosis of acute decompensated heart failure. objection to blood transfusion.

previous treatment with convalescent plasma for covid-19. current use of investigational antiviral therapy targeting sars-cov-2. history of anaphylactic transfusion reaction. clinical diagnosis of acute decompensated heart failure. objection to blood transfusion.

1. previous treatment with convalescent plasma for covid-19. 2. current use of investigational antiviral therapy targeting sars-cov-2. 3. history of anaphylactic transfusion reaction. 4. clinical diagnosis of acute decompensated heart failure. 5. objection to blood transfusion.

1. previous treatment with convalescent plasma for covid-19. 2. current use of investigational antiviral therapy targeting sars-cov-2. 3. history of anaphylactic transfusion reaction. 4. clinical diagnosis of acute decompensated heart failure. 5. objection to blood transfusion.